Using cancer genetics to guide the selection of anticancer drug targets

• 1 August 2002
• journal article
• review article
• Published by Elsevier in Current Opinion in Pharmacology
• Vol. 2  (4) , 366-373
• https://doi.org/10.1016/s1471-4892(02)00178-9

Abstract

Keywords

• IMATINIB MESYLATE
• SHORT INTERFERING RNAS
• SYNTHETIC LETHALITY
• ONCOPROTEINS
• KINASES
• CANCER BIOLOGY
• PHARMACOLOGY
• MOLECULAR MEDICINE